Lifeward Reports First Quarter 2024 Financial Results
May 15, 2024 08:00 ET
|
ReWalk Robotics Ltd. (DBA Lifeward)
Q1’24 revenue of $5.3M is up 340% vs. Q1’23 and at the midpoint of Lifeward’s guidance range Newly established Medicare payment for ReWalk Personal Exoskeleton favorably impacts Q1’24 results ...
Lifeward to Report First Quarter Financial Results on May 15, 2024
May 07, 2024 16:30 ET
|
ReWalk Robotics Ltd. (DBA Lifeward)
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader...
Lifeward Announces the Appointment of Mike Swinford to its Board of Directors
April 19, 2024 08:30 ET
|
ReWalk Robotics Ltd. (DBA Lifeward)
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 19, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market lead...
Medicare Revises 2024 Fee Schedule to Include Payment Rate for the ReWalk Personal Exoskeleton
April 12, 2024 08:30 ET
|
ReWalk Robotics Ltd. (DBA Lifeward)
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 12, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering...
Lifeward CEO Issues Open Letter to Shareholders on Progress to Finalize Exoskeleton Medicare Payment Rate
April 01, 2024 16:30 ET
|
ReWalk Robotics Ltd. (DBA Lifeward)
Collaboration with CMS on final payment rate focuses on commercial transaction values for the latest generation of ReWalk Exoskeleton CMS indicates that recently issued fee schedule which omitted...
VA STAND Act introduced in the United States Senate
March 22, 2024 08:30 ET
|
ReWalk Robotics Ltd. (DBA Lifeward)
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader...
Lifeward Announces Reverse Share Split
March 13, 2024 11:45 ET
|
ReWalk Robotics Ltd. (DBA Lifeward)
Reverse split initiated to regain compliance with Nasdaq listing requirements Financial guidance for 2024 and profitability target for 2026 on existing capital remain unchanged ...
ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy
March 08, 2024 08:30 ET
|
ReWalk Robotics Ltd. (DBA Lifeward)
Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving...
Lifeward announces the Centers for Medicare & Medicaid Services (“CMS”) is deferring its final decision on the payment rate for personal exoskeletons so that more recent claims information on the current, more advanced ReWalk Personal Exoskeleton may be considered
March 01, 2024 08:45 ET
|
ReWalk Robotics Ltd. (DBA Lifeward)
The decision was communicated through CMS’ bi-annual Healthcare Common Procedure Coding System (“HCPCS”) coding memorandum released yesterday; payment amount determination for ReWalk Personal...
Lifeward Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024 08:00 ET
|
ReWalk Robotics Ltd. (DBA Lifeward)
Highest quarterly and annual revenue in the history of LifewardCommercial and operational integration complete; synergiesexpected to yield $3 million in annual net savings MARLBOROUGH, Mass. and...